Arcutis Biotherapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-05$31.20 RISE2026-03-27$21.22 PEAK2026-04-14$25.09 130d | -32.0% 112d | Missed | Missed | — | — | +18.2% 18d | Missed |
DROP2025-03-24$17.29 RISE2025-05-30$13.04 PEAK2025-08-15$16.89 144d | -24.6% 67d | Missed | Missed | — | — | +29.5% 77d | Missed |
DROP2025-03-24$17.29 RISE2025-04-11$12.59 PEAK2025-05-05$15.41 42d | -27.2% 18d | Missed | Missed | — | — | +22.4% 24d | Missed |
DROP2025-01-07$15.76 RISE2025-02-11$11.40 PEAK2025-03-24$17.29 76d | -27.7% 35d | Missed | Missed | — | — | +51.7% 41d | Missed |
DROP2024-08-29$11.00 RISE2024-10-31$8.31 PEAK2025-01-07$15.76 131d | -24.5% 63d | Missed | Missed | — | — | +89.7% 68d | Missed |
DROP2024-08-29$11.00 RISE2024-10-21$8.31 PEAK2025-01-07$15.76 131d | -24.5% 53d | Missed | Missed | — | — | +89.7% 78d | Missed |
DROP2024-07-15$10.77 RISE2024-08-22$8.32 PEAK2024-08-29$11.00 45d | -22.7% 38d | Missed | Missed | — | — | +32.2% 7d | Missed |
DROP2024-04-08$12.53 RISE2024-06-07$7.24 PEAK2024-08-29$11.00 143d | -42.2% 60d | Missed | Missed | — | — | +51.9% 83d | Missed |
DROP2023-07-31$10.91 RISE2023-11-30$1.84 PEAK2024-02-27$10.63 211d | -83.1% 122d | Missed | Missed | — | — | +477.7% 89d | Missed |
DROP2023-02-15$17.14 RISE2023-05-31$7.51 PEAK2023-07-17$10.98 152d | -56.2% 105d | Missed | Missed | — | — | +46.2% 47d | Missed |
DROP2022-11-15$19.44 RISE2023-03-24$10.23 PEAK2023-05-03$15.00 169d | -47.4% 129d | Missed | Missed | — | — | +46.6% 40d | Missed |
DROP2022-09-01$26.87 RISE2023-01-11$13.53 PEAK2023-02-15$17.14 167d | -49.6% 132d | Missed | Missed | — | — | +26.7% 35d | Missed |
DROP2022-08-31$26.95 RISE2022-10-26$16.62 PEAK2022-11-10$19.48 71d | -38.3% 56d | Missed | Missed | — | — | +17.2% 15d | Missed |
DROP2022-07-11$25.61 RISE2022-08-02$19.50 PEAK2022-08-31$26.95 51d | -23.9% 22d | Missed | Missed | — | — | +38.2% 29d | Missed |
DROP2022-01-03$22.79 RISE2022-05-11$16.33 PEAK2022-07-11$25.61 189d | -28.3% 128d | Missed | Missed | — | — | +56.8% 61d | Missed |
1–15 / 24 1 / 2 | |||||||
Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, formulations, and prescriber...
In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other...
In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other...
WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 269,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 70,000 shares of Arcutis’ common stock to 40 newly hired employees. These awards were approved by the Compensation Committee of Arcutis
Moby summary of Arcutis Biotherapeutics, Inc.'s Q1 2026 earnings call
Moby summary of Arcutis Biotherapeutics, Inc.'s Q1 2026 earnings call
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
2026-05-07. The following slide deck was published by Arcutis Biotherapeutics, Inc.
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. First Quarter 2026 Earnings Conference Call. [Operator
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsBrian Schoelkopf - Head of Investor RelationsTodd...
Arcutis Biotherapeutics (NASDAQ:ARQT) reported first-quarter 2026 net product revenues of $105.4 million, a 65% increase versus the same period last year, as the company pointed to continued demand growth for its topical therapy ZORYVE and progress across a “grow, expand, build” strategy that includ
Arcutis Biotherapeutics (NASDAQ:ARQT) reported first-quarter 2026 net product revenues of $105.4 million, a 65% increase versus the same period last year, as the company pointed to continued demand growth for its topical therapy ZORYVE and progress across a “grow, expand, build” strategy that includ
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics beats Q1 revenue estimates but posts wider-than-expected loss, sending shares down 4.8%. ZORYVE sales surge 65% YoY to $105.4M, though full-year guidance trails analyst forecasts.
Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of branded non-steroidal topical treatmentsSubmitted supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the U.S. Food and Drug Administration (FDA) to expand the indication for the treatment of atopic dermatitis in infants ages 3 to 24 mo
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update Q1 2026 net product revenue for ZORYVE® was $105.4 million, a 65%...
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 55 percent increase over losses of $(0.20) per share
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARQT | -8.09% | -13.33% | -26.10% | +64.57% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.06% | -7.61% | -22.66% | +51.88% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.30M | $148.34M | 0.01% | Added+14.7% | 2026-03-31 |
| DEShaw | quant | 2.50M | $58.81M | 0.04% | Trimmed-7.0% | 2026-03-31 |
| Citadel | multi-strat | 590.9K | $13.92M | 0.02% | Added+39.0% | 2026-03-31 |
| RenTech | quant | 441.0K | $10.39M | 0.02% | Added+60.9% | 2026-03-31 |
| FidelityFMR | fundamental | 278.7K | $6.57M | 0.00% | Added+35.7% | 2026-03-31 |
| TwoSigma | quant | 234.3K | $5.52M | 0.00% | Trimmed-41.5% | 2026-03-31 |
| Wellington | fundamental | 44.4K | $1.05M | 0.00% | Trimmed-3.9% | 2026-03-31 |
| TRowePrice | fundamental | 448.2K | $10.56K | 0.00% | Trimmed-61.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.05 | — | — |
| 2026-05-06 | -0.06 | -0.09 | -55.17% |
| 2026-02-25 | 0.09 | 0.13 | +46.78% |
| 2025-10-28 | -0.09 | 0.06 | +163.63% |
| 2025-08-06 | -0.16 | -0.13 | +17.89% |
| 2025-05-06 | -0.21 | -0.20 | +4.76% |
| 2025-02-25 | -0.26 | -0.09 | +65.95% |
| 2024-11-06 | -0.42 | -0.33 | +22.35% |
| 2024-08-14 | -0.53 | -0.42 | +20.75% |
| 2024-05-14 | -0.73 | -0.32 | +56.16% |
| 2024-02-27 | -0.80 | -0.72 | +10.00% |
| 2023-11-03 | -0.91 | -0.73 | +20.07% |
| 2023-08-08 | -1.25 | -1.16 | +6.99% |
| 2023-05-09 | -1.26 | -1.31 | -3.62% |
| 2023-02-28 | -1.44 | -1.18 | +17.81% |
| 2022-11-08 | -1.75 | -1.89 | -7.85% |